AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27878824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)-based approach
Number of subjects: 254
Study 27878824 — intervention group
Group type: COMPARATOR
Intervention: Standard care approach
Number of subjects: 254
Study 27878824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 254
Study 25726153 — intervention group
Group type: EXPERIMENTAL
Intervention: Student Assistance Programme
Number of subjects: 15
Study 25726153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention training
Number of subjects: 15
Study 25726153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention assessment
Number of subjects: 15
Study 25726153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clarification
Number of subjects: 15
Study 25726153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention responsibility
Number of subjects: 15
Study 23320655 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care management for dementia
Number of subjects: 0
Study 23320655 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 20637053 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3-β-d-glucan-containing nutritional supplement
Number of subjects: 6
Study 18974448 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedal standing therapy (3 times a day for an unspecified duration)
Number of subjects: 86
Study 18974448 — intervention group
Group type: COMPARATOR
Intervention: Unipedal standing therapy
Number of subjects: 86
Study 16550299 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg weekly
Number of subjects: 98
Study 16550299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ALN, receiving calcium and calcitriol)
Number of subjects: 98
Study 12741307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparine (100 IU/kg twice daily) for an average duration of 13 days, followed by fluindione starting on the fifth day.
Number of subjects: 19
Study 11107867 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten free diet (GFD) for 11.7 years
Number of subjects: 73
Study 11107867 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten free diet (GFD)
Number of subjects: 73
Study 8869692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (2.5 mg/kg/day)
Number of subjects: 30
Study 8869692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1512185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (maximal BALs of 0.05 or 0.10)
Number of subjects: 44
Study 1512185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (ascending BALs)
Number of subjects: 44
Study 1512185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol treatment (maximal intoxication)
Number of subjects: 44
Study 1512185 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study 6861866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lorcainide tablets taken at 0, 12 and 24 h
Number of subjects: 25
Study 6861866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lorcainide tablets taken at 0, 1, 12 and 24 h
Number of subjects: 25
Study 6861866 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lorcainide tablets taken at 0, 2, 12 and 24 h
Number of subjects: 25
Study 30755027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention group
Number of subjects: 1261
Study 30755027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 1261
Study 30755027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of life
Number of subjects: 1261
Study 30755027 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina frequency
Number of subjects: 1261
Study 30755027 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical limitation scale
Number of subjects: 1261
Study 30755027 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex differences in physical limitations
Number of subjects: 1261
Study 29048455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (games focusing on food pyramid and physical activity)
Number of subjects: 89
Study 29048455 — intervention group
Group type: COMPARATOR
Intervention: Control group (informative session about food pyramid and physical activity)
Number of subjects: 89
Study 26140541 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (maltodextrin)
Number of subjects: 33
Study 26140541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid (dairy-cream)
Number of subjects: 33
Study 26140541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 33
Study 24787767 — intervention group
Group type: EXPERIMENTAL
Intervention: Restore intervention
Number of subjects: 83
Study 22647148 — intervention group
Group type: EXPERIMENTAL
Intervention: media-supported 4-step approach
Number of subjects: 220
Study 22647148 — intervention group
Group type: COMPARATOR
Intervention: standard 4-step approach
Number of subjects: 220
Study 19270819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (sprayed onto the axillary dissection site)
Number of subjects: 100
Study 19270819 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 100
Study 17900408 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg/day)
Number of subjects: 42
Study 17900408 — intervention group
Group type: COMPARATOR
Intervention: Rilmazafone (2 mg/day)
Number of subjects: 42
Study 15482064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional theory applied to recognition of celebrity faces
Number of subjects: 0
Study 15482064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional theory applied to recognition of unfamiliar faces
Number of subjects: 0
Study 15482064 — intervention group
Group type: COMPARATOR
Intervention: Linear theory applied to recognition tasks
Number of subjects: 0
Study 11525272 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene hydrochloride, 60 mg/d for 6 months
Number of subjects: 29
Study 9801723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Focus Schema Therapy (manual-guided individual cognitive-behavioral therapy) for 24 weeks
Number of subjects: 0
Study 9801723 — intervention group
Group type: COMPARATOR
Intervention: 12-Step Drug Counseling
Number of subjects: 0
Study 7949701 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygapophysial joint injections or blocks of the medial branches of the dorsal ramus with lignocaine
Number of subjects: 176
Study 7949701 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory blocks using bupivacaine
Number of subjects: 176
Study 2897433 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 497
Study 2897433 — intervention group
Group type: COMPARATOR
Intervention: FAC (fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 497
Study 2897433 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC
Number of subjects: 497
Study 2897433 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 497
Study 29564750 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dressing formulated with 0.1% P1G10
Number of subjects: 50
Study 29564750 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel (control)
Number of subjects: 50
Study 27792728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological manipulation of catecholamine activity
Number of subjects: 32
Study 27792728 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 component of EEG
Number of subjects: 32
Study 27792728 — intervention group
Group type: EXPERIMENTAL
Intervention: P3 amplitude
Number of subjects: 32
Study 23801785 — intervention group
Group type: EXPERIMENTAL
Intervention: Active valve circuit
Number of subjects: 20
Study 23801785 — intervention group
Group type: COMPARATOR
Intervention: Leak port circuit
Number of subjects: 20
Study 23801785 — intervention group
Group type: COMPARATOR
Intervention: Leak port circuit with artificial leakage
Number of subjects: 20
Study 24326198 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (near-infrared light, continuous 850-nm wavelength, power density of 60 mW/cm2 for 20 or 30 min/day or 60 min/week, total energy densities of 72, 108, or 216 J/cm2)
Number of subjects: 90
Study 24326198 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional orthodontic treatment without photobiomodulation)
Number of subjects: 90
Study 24326198 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 24326198 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 90
Study 21275167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizhongxiao Decoction (BZXD)
Number of subjects: 18
Study 21275167 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 18
Study 21275167 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 18163011 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 20)
Number of subjects: 40
Study 18163011 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) (n = 20)
Number of subjects: 40
Study 18163011 — intervention group
Group type: COMPARATOR
Intervention: Control group (euthyroid females)
Number of subjects: 40
Study 15464664 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe-Cross radiofrequency guidewire
Number of subjects: 116
Study 11986705 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B inactivated vaccine against HFRS
Number of subjects: 588
Study 11986705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 588
Study 9736850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 minutes study time
Number of subjects: 0
Study 9736850 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 minute 15 seconds study time
Number of subjects: 0
Study 9736850 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds study time
Number of subjects: 0
Study 9736850 — intervention group
Group type: EXPERIMENTAL
Intervention: All expertise levels under constrained processing time
Number of subjects: 0
Study 9736850 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts' recall under constrained processing time
Number of subjects: 0
Study 7801390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (40 mW in 60 sec per cm tender tibia edge)
Number of subjects: 49
Study 7801390 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 49
Study 3294038 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) controlled-release tablets, 300 mg b.i.d.
Number of subjects: 116
Study 3294038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 30382308 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid resuscitation regimen
Number of subjects: 99
Study 30382308 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 27289174 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemopoietic stem-cell gene therapy (HSC-GT) with autologous HSCs transduced with a lentiviral vector encoding ARSA cDNA after busulfan conditioning
Number of subjects: 9
Study 24715381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 2-5 years
Number of subjects: 742
Study 23378751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits with alert buttons (NV+AB)
Number of subjects: 133
Study 23378751 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 133
Study 19934404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor (celecoxib; 200 mg/dose, 600 mg total)
Number of subjects: 16
Study 19934404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19934404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor
Number of subjects: 16
Study 18385262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal instillation of midazolam (0.2 mg kg(‐1))
Number of subjects: 10
Study 18385262 — intervention group
Group type: COMPARATOR
Intervention: Nebulized administration of midazolam (0.2 mg kg(‐1))
Number of subjects: 10
Study 16780390 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 5 mg/day (n = 10)
Number of subjects: 27
Study 16780390 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day (n = 9)
Number of subjects: 27
Study 16780390 — intervention group
Group type: COMPARATOR
Intervention: control (usual treatment; n = 8)
Number of subjects: 27
Study 15144293 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 15144293 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 15144293 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and high thoracic epidural analgesia
Number of subjects: 30
Study 11133623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 100
Study 11133623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 10 microg
Number of subjects: 100
Study 11133623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 15 microg
Number of subjects: 100
Study 11133623 — intervention group
Group type: COMPARATOR
Intervention: Control (ropivacaine 0.2% alone)
Number of subjects: 100
Study 10093379 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard electrode placement procedure
Number of subjects: 80
Study 10093379 — intervention group
Group type: COMPARATOR
Intervention: Modified electrode placement procedure
Number of subjects: 80
Study 7646633 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bassini operation
Number of subjects: 265
Study 7646633 — intervention group
Group type: COMPARATOR
Intervention: Shouldice procedure
Number of subjects: 265
Study 3042826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV; delivered by Percussionaire VDR 1 at 10 Hz)
Number of subjects: 8
Study 3042826 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV; delivered by a Siemens Servo 900 C)
Number of subjects: 8
Study 30853012 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional measurement of serum C-reactive protein (CRP)
Number of subjects: 160
Study 28632527 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthetic block
Number of subjects: 61
Study 28632527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 26355647 — intervention group
Group type: EXPERIMENTAL
Intervention: High central load (2-back)
Number of subjects: 0
Study 26355647 — intervention group
Group type: COMPARATOR
Intervention: Low central load (1-back)
Number of subjects: 0
Study 24432670 — intervention group
Group type: EXPERIMENTAL
Intervention: PMC therapy combined with LFJC (Langchuang Fuzheng Jiedu Capsule)
Number of subjects: 60
Study 24432670 — intervention group
Group type: EXPERIMENTAL
Intervention: PMC therapy combined with LFJC
Number of subjects: 60
Study 21596725 — intervention group
Group type: COMPARATOR
Intervention: NICE (National Institute for Health and Clinical Excellence)
Number of subjects: 216
Study 21596725 — intervention group
Group type: COMPARATOR
Intervention: SIGN (Scottish Intercollegiate Guideline Network)
Number of subjects: 216
Study 21596725 — intervention group
Group type: COMPARATOR
Intervention: GRADE (Grading of Recommendations Assessment, Development and Evaluation)
Number of subjects: 216
Study 21596725 — intervention group
Group type: COMPARATOR
Intervention: CEBM (Centre for Evidence‐Based Medicine, Oxford)
Number of subjects: 216
Study 19638231 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended questionnaire (A)
Number of subjects: 350
Study 19638231 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-ended questionnaire with deceptive response items (B)
Number of subjects: 350
Study 19638231 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-ended questionnaire with only correct items (C)
Number of subjects: 350
Study 16211618 — intervention group
Group type: COMPARATOR
Intervention: rTMS (25 Hz)
Number of subjects: 18
Study 12457031 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (GRN) alone (3 mg/patient)
Number of subjects: 69
Study 12457031 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (CCT) with Granisetron (GRN), Methylprednisolone (MPD) (250 mg/patient), and Droperidol (DRP) (0.5 ml/patient)
Number of subjects: 69
Study 12457031 — intervention group
Group type: COMPARATOR
Intervention: CMB group (GRN and MPD)
Number of subjects: 69
Study 12457031 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT group
Number of subjects: 69
Study 12457031 — intervention group
Group type: COMPARATOR
Intervention: GRN group
Number of subjects: 69
Study 10657866 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 70
Study 10657866 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone
Number of subjects: 70
Study 9288386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 58
Study 9288386 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 58
Study 8363290 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 524
Study 8363290 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 524
Study 8363290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide
Number of subjects: 524
Study 8363290 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine plus 0.5% tropicamide
Number of subjects: 524
Study 8363290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide alone or in combination with phenylephrine
Number of subjects: 524
Study 3092196 — intervention group
Group type: COMPARATOR
Intervention: hGRF 2.5 micrograms
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF 5 to 80 micrograms
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF above 80 micrograms
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF 80 micrograms
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF 100, 300, and 600 micrograms (subcutaneous administration)
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF 600 micrograms
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF doses above 80 micrograms
Number of subjects: 0
Study 3092196 — intervention group
Group type: EXPERIMENTAL
Intervention: hGRF doses less than 80 micrograms
Number of subjects: 0
Study 31133040 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity intervention for six months
Number of subjects: 100
Study 27809592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 260
Study 27809592 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 260
Study 27809592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tamsulosin and Solifenacin
Number of subjects: 260
Study 25944940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 12
Study 25944940 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 5 cm H2O
Number of subjects: 12
Study 25944940 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (non-rebreathing face mask)
Number of subjects: 12
Study 24837026 — intervention group
Group type: EXPERIMENTAL
Intervention: Test to calculate the probability of viability (cases)
Number of subjects: 69
Study 24837026 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (controls)
Number of subjects: 69
Study 22101218 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART)
Number of subjects: 154
Study 22101218 — intervention group
Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 154
Study 19037197 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol in CYP2D6 poor metabolizers (PMs)
Number of subjects: 0
Study 19037197 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol in non‐poor metabolizers (non‐PMs)
Number of subjects: 0
Study 17151339 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg rhGAA
Number of subjects: 18
Study 17151339 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg rhGAA
Number of subjects: 18
Study 17151339 — intervention group
Group type: COMPARATOR
Intervention: rhGAA (both doses)
Number of subjects: 18
Study 15096906 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 164
Study 15096906 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 164
Study 15096906 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg or Amlodipine 10 mg (after up-titration)
Number of subjects: 164
Study 15096906 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + Hydrochlorothiazide (12.5 mg)
Number of subjects: 164
Study 15096906 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Hydrochlorothiazide (12.5 mg)
Number of subjects: 164
Study 11429364 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg amantadine IV in 500 mL saline
Number of subjects: 30
Study 11429364 — intervention group
Group type: COMPARATOR
Intervention: 500 mL saline IV (Control group)
Number of subjects: 30
Study 9554288 — intervention group
Group type: EXPERIMENTAL
Intervention: OMV vaccine with aluminium hydroxide and serogroup C-polysaccharide (C-ps)
Number of subjects: 0
Study 9554288 — intervention group
Group type: EXPERIMENTAL
Intervention: OMV vaccine without aluminium hydroxide
Number of subjects: 0
Study 9554288 — intervention group
Group type: EXPERIMENTAL
Intervention: OMV vaccine adsorbed to aluminium hydroxide
Number of subjects: 0
Study 8052950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level energy infra-red laser irradiation (4 minutes, total dose = 1J)
Number of subjects: 10
Study 8052950 — intervention group
Group type: COMPARATOR
Intervention: Ordinary light (control)
Number of subjects: 10
Study 2648787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 18
Study 2648787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18